Key Highlights
- Dr. Laura Aguilar named Chief Medical Officer at Diakonos Oncology.
- DOC1021 dendritic cell vaccine to enter Phase 2 clinical trial for glioblastoma (GBM).
- Deancy Okoebor and Eva Highberg Schumann join clinical operations team.
- FDA Fast Track and Orphan Drug Designation for GBM program secured.
Source: Business Wire
Notable Quotes
- “I believe Diakonos’ dendritic cell vaccines may represent a first-of-its-kind strategy for engaging a complete immune response to attack cancer.” — Dr. Laura Aguilar, M.D., Ph.D. – Chief Medical Officer at Diakonos Oncology
- “Her entrepreneurial background, clinical development expertise, and physician-patient experience will be essential in advancing our pipeline of highly differentiated dendritic cell vaccines.” — Mike Wicks, CEO at Diakonos Oncology
SoHC's Take
Dr. Laura Aguilar’s appointment as Chief Medical Officer signifies a strategic move by Diakonos Oncology to solidify its leadership in immuno-oncology. Her extensive experience in developing biologics and spearheading clinical innovations positions the company for success as it progresses its dendritic cell vaccine, DOC1021, into Phase 2 trials for glioblastoma. This therapy’s unique double loading technology represents a promising frontier in engaging a comprehensive immune response. With FDA designations for glioblastoma and pancreatic cancer, Diakonos is strategically positioned to address unmet needs in some of the most challenging cancer types.
